Neuros Medical highlights quality-of-life gains from its Altius system
QUEST study participants reported a 45% increase in quality of life and improvements in sleep, walking, working and relationships.
See the latest news and media coverage for Neuros Medical. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical device company providing treatment for chronic post-amputation pain
neurosmedical.comLast updated
In short: Neuros Medical received Medicare transitional pass-through status for ALTIUS, effective January 2027.
QUEST study participants reported a 45% increase in quality of life and improvements in sleep, walking, working and relationships.
CMS finalizes the status in the CY 2027 OPPS and ASC rule, effective January 1, 2027, giving separate device reimbursement above the procedural rate.
The oversubscribed round is led by EQT Life Sciences with existing investors and funds U.S. commercialization of its FDA-approved Altius nerve stimulation system.
The implanted, patient-controlled device treats chronic intractable phantom and residual lower limb post-amputation pain in adult amputees, based on the QUEST trial. Commercialization is planned for later this year.
ALISO VIEJO, Calif., July 23, 2025 /PRNewswire/ -- In a major milestone for chronic post-amputation pain treatment, the first commercial patient in the U.S. has...
Neuros Medical, the maker of the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain, announced an oversubscribed $56 million Series D financing...
STOCKHOLM, July 9, 2025 /PRNewswire/ -- EQT Life Sciences ("EQT") is pleased to announce that the LSP 7 fund and the EQT Health Economics strategy...
/PRNewswire/ -- Neuros Medical, Inc., the maker of the Altius® Direct Electrical Nerve Stimulation System, an FDA-approved, breakthrough non-opioid treatment...
Track Neuros Medical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.